Cisplatin, vindesine, pepleomycin and concurrent radiation therapy following esophagectomy with lymph adenectomy for patients with an esophageal carcinoma.
Between 1986 and 1991, 35 patients with esophageal cancer (TNM stages II-IV) underwent transthoracic esophagectomy with lymph adenectomy and were subsequently treated with 5,000 cGy of radiation (days 1-40) and concurrently with two courses of chemotherapy (cisplatin, vindesine and pepleomycin, days 21-26 and 49-54). Results were compared with those of 26 historical control patients, treated with radiation since 1981. Tolerance in all patients was good. The survival rate at 5 years was significantly improved for the multimodality-treated patients (30.9 +/- 9.4%), as compared with findings in historical controls (5.1 +/- 4.8%). The concurrent chemoradiation therapy using these three drugs following extensive surgery is worthy of consideration for patients with a localized esophageal cancer.
Saito
T
T
Department of Surgery I, Oita Medical University, Japan.
Shigemitsu
Y
Y
Kinoshita
T
T
Shimoda
K
K
Abe
T
T
Nakamura
A
A
Chikuba
K
K
Kobayashi
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016629:Esophagectomy; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D017663:Peplomycin; D011879:Radiotherapy Dosage; D013997:Time Factors; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
D001761:Bleomycin; D017663:Peplomycin; D002945:Cisplatin; D014751:Vindesine